Norwegian-developed heart medicine with a major agreement in Greece

Coxor®, 300mg acetylsalicylic acid, is the first and only ready to use oral liquid acetylsalicylic acid for immediate use in case of suspected acute myocardial infarction (heart attacks). The product has been approved in a European DCP process and is marketed in Norway as an OTC (over-the-counter) drug. It’s the first drug of its kind for emergency treatment of myocardial infarction and is patented in large parts of the world. Ischaemic Heart Disease affects about 200 million people globally and is the leading cause of death with around 9 million fatalities annually. The product became available in Norwegian pharmacies in February 2023.

"We have long seen the potential of liquid acetylsalicylic acid in the treatment of acute myocardial infarction. Seeing that the product works and has been well-received in the domestic market, we are very excited to launch Coxor® in Greece," says Georgios Kritsionis, Director of Portfolio Management of Innovis Pharma.

"We are very satisfied with the development in Norway so far. We know that the product can have great international potential. In a short time, we have signed agreements with two significant partners outside the Nordics, and we are in advanced negotiations with many other companies regarding other countries and regions," says Geir Ivar Westen, CEO of Asamedic.

The agreement between Asamedic and Innovis Pharma currently spans 10 years, and the company has already started the national registration process for the product. The agreement is based on normal royalty rates and milestone payments, with Innovis Pharma being responsible for all marketing and sales.

Chairman Leif Thoring of the Board at Asamedic is pleased that the company's international ambitions are now being realized.

"The international interest is increasing. We have recently signed two agreements for Coxor® outside the Nordics, and the company has significant international ambitions. We firmly believe that a product that can save lives in this way will be of interest to both financial and industrial international players," says Thoring,

For inquiries or questions about Asamedic, please contact Geir Ivar Westen, CEO of Asamedic, phone: +47 90546049 or email: geirivar@asamedic.no.

About Asamedic AS
Asamedic was founded in Oslo in 2015, based on the idea of entrepreneur Per Erik Stribolt-Halvorsen to develop a liquid variant of ASA. There are currently 83 shareholders in Asamedic, many of them from within the medical field. You can read more about Asamedic at www.asamedic.no.

About Innovis Pharma

Innovis Pharma is a leading Greek pharmaceutical company, formed in 2018, delivering high-quality, patient-centric healthcare solutions covering all major therapeutic areas with GX & Innovative products, while also marketing established and developing OTC products and Cosmetics. You can read more about Innovis Pharma at https://www.innovispharma.gr/